Construction of optimized bispecific antibodies for selective activation of the death receptor CD95

Cancer Research

Volumn 68, Issue 4, 2008, Pages 1221-1227

  Herrmann, Tanja ^a   Große Hovest, Ludger ^a   Otz, Tina ^a   Krammer, Peter H ^b   Rammensee, Hans Georg ^a   Jung, Gundram ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 CD95 ANTIBODY; CD95 CROSSLINKING ANTIBODY; CYCLOHEXIMIDE; DEATH RECEPTOR; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR CD95 ANTIBODY; FAS ANTIBODY; FAS ANTIGEN; IMMUNOGLOBULIN F(AB')2 FRAGMENT; NEURONAL GLIAL ANTIGEN 2; NEURONAL GLIAL ANTIGEN 2 CD95 ANTIBODY; RECOMBINANT ANTIBODY; TENASCIN; TENASCIN CD95 ANTIBODY; TOPOTECAN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIBODY ENGINEERING; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CIS ISOMER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HYBRIDIZATION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; RECEPTOR UPREGULATION; TARGET CELL; TRANS ISOMER;

AMINO ACID SEQUENCE; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS, CD95; ANTIGENS, NEOPLASM; APOPTOSIS; CELL LINE, TUMOR; DOXORUBICIN; GLIOBLASTOMA; HUMANS; IMMUNOGLOBULIN FRAGMENTS; MOLECULAR SEQUENCE DATA; TOPOTECAN;

EID: 39449129555     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6175     Document Type: Article

References (25)

1. Krammer PH. CD95′s deadly mission in the immune system. Nature 2000;407:789-95.
2. Nagata S, Golstein P. The Fas death factor. Science 1995;267:1449-56.
3. Dhein J, Daniel PT, Trauth BC, Oehm A, Moller P, Krammer PH. Induction of apoptosis by monoclonal antibody anti-APO-1 class switch variants is dependent on cross-linking of APO-1 cell surface antigens. J Immunol 1992;149:3166-73.
4. Trauth BC, Klas C, Peters AM, et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989;245:301-5.
5. Yonehara S, Ishii A, Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med 1989;169:1747-56.
6. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature 1993;364:806-9.
7. Ichikawa K, Yoshida-Kato H, Ohtsuki M, et al. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int Immunol 2000;12:555-62.
8. Feng G, Kaplowitz N. Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibody. J Clin Invest 2000;105:329-39.
9. Jung G, Grosse-Hovest L, Krammer PH, Rammensee HG. Target cell-restricted triggering of the CD95 (APO-1/Fas) death receptor with bispecific antibody fragments. Cancer Res 2001;61:1846-8.
10. Samel D, Muller D, Gerspach J, et al. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J Biol Chem 2003;278:32077-82.
11. Bullani RR, Wehrli P, Viard-Leveugle I, et al. Frequent downregulation of Fas (CD95) expression and function in melanoma. Melanoma Res 2002;12:263-70.
12. Xerri L, Bouabdallah R, Devilard E, Hassoun J, Stoppa AM, Birg F. Sensitivity to Fas-mediated apoptosis is null or weak in B-cell non-Hodgkin's lymphomas and is moderately increased by CD40 ligation. Br J Cancer 1998;78:225-32.
13. Mehlen P, Puisieux A. Metastasis: a question of life or death. Nat Rev Cancer 2006;6:449-58.
14. Ciusani E, Perego P, Carenini N, et al. Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors. Biochem Pharmacol 2002;63:881-7.
15. Wu XX, Mizutani Y, Kakehi Y, Yoshida O, Ogawa O. Enhancement of Fas-mediated apoptosis in renal cell carcinoma cells by adriamycin. Cancer Res 2000;60:2912-8.
16. Fulda S, Kufer MU, Meyer E, van Valen F, Dockhorn-Dworniczak B, Debatin KM. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene 2001;20:5865-77.
17. Peart MJ, Tainton KM, Ruefli AA, et al. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res 2003;63:4460-71.
18. Zhang B, Prendergast GC, Fenton RG. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression. Cancer Res 2002;62:450-8.
19. Jung G, Freimann U, Von Marschall Z, Reisfeld RA, Wilmanns W. Target cell-induced T cell activation with bi- and trispecific antibody fragments. Eur J Immunol 1991;21:2431-5.
20. Grosse-Hovest L, Muller S, Minoia R, et al. Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci U S A 2004;101:6858-63.
21. Grosse-Hovest L, Hartlapp I, Marwan W, Brem G, Rammensee HG, Jung G. A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing. Eur J Immunol 2003;33:1334-40.
22. Chiquet-Ehrismann R, Chiquet M. Tenascins: regulation and putative functions during pathological stress. J Pathol 2003;200:488-99.
23. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389-97.
24. Fulda S, Wick W, Weller M, Debatin KM. Smac agonists sensitize for Apo2L/T. Nat Med 2002;8:808-15.
25. Gajate C, Canto-Janez E, Acuna AU, et al. Intracellular triggering of Fas aggregation and recruitment of apoptotic molecules into Fas-enriched rafts in selective tumor cell apoptosis. J Exp Med 2004;200:353-65.